EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study

Aiko Fukui, Ryosuke Ota, Atsushi Hirata

Int. Journal of Clinical Pharmacology and Therapeutics · 01.11.2026 · 64 (11) · 570-581

DOI: 10.5414/cp204974 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 01.11.2026. Verfasst von Aiko Fukui und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cachexia, Hydrazines, Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCachexiaHydrazinesNeoplasmsOligopeptidesAgedFemaleHumansMaleMiddle AgedJapanRetrospective StudiesRisk Factors

Substanzen

anamorelinAntineoplastic AgentsHydrazinesOligopeptides

Zitieren

APA

Fukui, A., Ota, R., & Hirata, A. (2026). Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study. Int. Journal of Clinical Pharmacology and Therapeutics, 64(11), 570-581. https://doi.org/10.5414/cp204974

Vancouver

Fukui A, Ota R, Hirata A. Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study. Int. Journal of Clinical Pharmacology and Therapeutics. 2026;64(11):570-581. doi:10.5414/cp204974

BibTeX
@article{Fukui2026,
  author = {Fukui, Aiko and Ota, Ryosuke and Hirata, Atsushi},
  title = {Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2026},
  volume = {64},
  number = {11},
  pages = {570--581},
  doi = {10.5414/cp204974}
}
Kostenlos starten →